Literature DB >> 2195892

Advances in primary sclerosing cholangitis.

K D Lindor1, R H Wiesner, R L MacCarty, J Ludwig, N F LaRusso.   

Abstract

Primary sclerosing cholangitis is an increasingly recognized chronic cholestatic liver disease. It frequently occurs in association with chronic ulcerative colitis and is characterized by inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts. The cause is unknown, although many mechanisms have been considered, including infectious, toxic, and immunologic. The prognosis varies. No adequate treatment exists, although a number of potential treatments have been evaluated in uncontrolled trials, and the results of controlled trials have only recently been reported. Liver transplantation has recently been shown to be an effective treatment for end-stage disease. These various advances in our understanding of primary sclerosing cholangitis are reviewed.

Entities:  

Mesh:

Year:  1990        PMID: 2195892     DOI: 10.1016/0002-9343(90)90101-i

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Primary sclerosing cholangitis associated with lupus nephritis: a rare association.

Authors:  Yoshiko Kadokawa; Katsuhisa Omagari; Isao Matsuo; Yoshiko Otsu; Umpei Yamamoto; Tomoya Nishino; Kazuo Ohba; Masanobu Miyazaki; Takashi Harada; Takashi Taguchi; Shigeru Kohno
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

3.  Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.

Authors:  J A Goss; C R Shackleton; D G Farmer; W S Arnaout; P Seu; J S Markowitz; P Martin; R J Stribling; L I Goldstein; R W Busuttil
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

Review 4.  Infectious complications of liver disease.

Authors:  P D King
Journal:  J Gen Intern Med       Date:  1993-06       Impact factor: 5.128

5.  The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation.

Authors:  A Shaked; J O Colonna; L Goldstein; R W Busuttil
Journal:  Ann Surg       Date:  1992-06       Impact factor: 12.969

6.  Experimental colitis in rats induces low-grade endotoxinemia without hepatobiliary abnormalities.

Authors:  H S Brand; M A Maas; A Bosma; R J Van Ketel; P Speelman; R A Chamuleau
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

7.  Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease.

Authors:  Folashade Adebisi Jose; Elizabeth A Garnett; Eric Vittinghoff; George D Ferry; Harland S Winter; Robert N Baldassano; Barbara S Kirschner; Stanley A Cohen; Benjamin D Gold; Oren Abramson; Melvin B Heyman
Journal:  Inflamm Bowel Dis       Date:  2009-01       Impact factor: 5.325

8.  Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial.

Authors:  D H Van Thiel; P Carroll; K Abu-Elmagd; H Rodriguez-Rilo; W Irish; J McMichael; T E Starzl
Journal:  Am J Gastroenterol       Date:  1995-03       Impact factor: 10.864

9.  Experimental colitis attenuates development of toxin-induced cholangitis in rats.

Authors:  Kartika Tjandra; Tai Le; Mark G Swain
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.